November 6 – 9, 2023 | Boston, MA
Recent approvals from Sarepta, Bluebird Bio, and PTC Therapeutics, and news of expanding CNS pipelines have highlighted that we are currently on the cusp of a next-generation of neurological gene therapies, and the 5th Gene Therapy for Neurological Disorders Summit is here to help you propel the next wave of innovation.
This meeting will enable you to overcome your Discovery, Preclinical and Clinical development challenges, from capsid engineering to preclinical model selection, immunogenicity, drug delivery, and regulation; this is the only cover-to-cover, comprehensive 4-day discussion full of need-to-know and practical insights.
Now that the neurological gene therapy field has been given a renewed sense of direction, this is the opportunity for the community to capitalize on the start of a new wave of innovation and optimize the potential for gene therapies targeting neurological disorders.
Join your peers this November from all phases of neurological gene therapy development, including Discovery, Preclinical Development, Translation, and Clinical Development. Joining the clinical development stream, Beacon’s Research Lead, Costanza Gorini, for a review of the current animal model trends for Neurological Gene Therapies, so make sure to join the team at 2:30pm on November 7 for some exclusive data insights.